• 079MBC Banner 1150x300



Breast cancer accounts for nearly 30% of cancer diagnoses among women in the United States, and is the second-leading cause of cancer death in this population. Although many women benefit from regular screening as well as earlier and improved treatment, approximately 10% present with metastatic disease, and 30% with no initial lymph node involvement eventually develop metastatic disease. Women with metastatic breast cancer (MBC) have a poorer prognosis than the overall population of breast cancer patients, and issues such as refractory or resistant disease, cumulative toxicities, adverse events, depression, and financial hardship are often encountered. Despite progress in understanding the pathogenesis of MBC and advances in therapy, the 5-year overall survival rate remains only 22%.


Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the management of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.


Upon completion of this activity, participants should be able to:

  • Describe patient- and disease-related factors that can inform individualized treatment planning in HR-positive, HER2-negative MBC
  • Differentiate therapeutic and safety profiles of CDK4/6 inhibitors in HR-positive, HER2-negative MBC
  • Apply supportive care strategies to mitigate adverse events associated with CDK4/6 inhibitors and promote adherence to therapy


There is no fee to participate in or claim CE credit for this activity. 

Please note that the USF Health and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.

Jointly Provided by

USF Health Logo   i3 Health Logo

USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity.


USF Health and i3 Health endorse the standards of the ANCC that require everyone in a position to control the content of a CE activity to disclose all financial relationships with commercial interests that are related to the content of the CE activity. CE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when individuals in a position to control the content of CE have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. USF Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. USF Health does not endorse any products or services.

Planning Committee, USF Health OCPD staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.

Disclosures are on file at the USF Health Office of Continuing Professional Development.


No prerequisites are required for this activity.


Participants must sign-in before the start of the activity to verify attendance.  All participants are asked to complete a pretest and a posttest for outcomes assessment; a passing score is not required.  At the conclusion of the activity participants must complete an evaluation, attesting to the time spent in this live activity, claiming credit. Certificates of Completion will be emailed to participants within two weeks of the activity.


USF Health and i3 Health require CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.


USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.


This activity is supported by an independent educational grant from Lilly.


Technical queries about this activity should be directed to This email address is being protected from spambots. You need JavaScript enabled to view it..

Questions regarding activity credit should be directed to This email address is being protected from spambots. You need JavaScript enabled to view it..